In companion animal tablet and capsule manufacturing, the tincture-grade veterinary API is first assessed for residual solvent profile under VICH GL18 because tincture-derived feedstocks may retain ethanol, methanol, or isopropanol above permitted daily exposure limits. Where headspace GC assay shows ethanol above 5000 ppm, the API is vacuum-dried at 40 °C and −0.08 MPa for 8–24 h before particle size reduction. Size reduction by jet milling or pin milling targets a D₅₀ of 25–75 µm as determined by laser diffraction according to ISO 13320:2020. Direct compression operates within an API addition ratio of 2.0–12.5% w/w; chewable tablets may reach 15.0% w/w because the palatant-laden base contributes a larger diluent volume without proportionally increasing the active fraction. Blend uniformity is tested after mixing in a 600 L V-blender at 20 rpm for 20 min; sampling at ten locations under 21 CFR 211.110 must demonstrate assay RSD ≤5.0%. Compression on a rotary tablet press uses precompression force 2–4 kN and main compression force 6–12 kN. Production-scale experience shows that higher precompression force commonly induces lamination in low-moisture direct-compression placebo runs before the active granulation is introduced. Hardness is controlled at 40–80 N, friability at ≤1.0% under USP <1216>, and disintegration at <15 min in 0.1 M HCl according to Ph. Eur. 2.9.1. Capsule filling on an automatic tamping pin machine at 30–60 cycles/min uses shell sizes 0–4, with mass uniformity evaluated under Ph. Eur. 2.9.5 and content uniformity under USP <905>. Terminal product types include film-coated tablets, uncoated tablets, chewable tablets, and hard gelatin capsules.

Why Does Terminal Filtration Alone Not Create a Sterility Margin for Heat-Sensitive Veterinary Injectable Solutions?

Injectable production lines require a documented bioburden control strategy for the non-sterile API fraction because terminal filtration alone does not remove pre-filtration endotoxin loading and does not protect against filter rupture or downstream contamination. The tincture-grade veterinary API is dissolved or dispersed in Water for Injection at 0.05–5.0% w/v after assay adjustment for as-is potency. If residual ethanol from the tincture exceeds 1000 ppm, concentrated solution is processed by rotary evaporation or diafiltration before final volume makeup to prevent osmolality drift and limit co-solvent toxicity. The bulk solution is buffered to pH 6.5–7.5 and adjusted to osmolality 280–320 mOsm/kg with sodium chloride 0.9% w/v or mannitol 4.5–5.5% w/v. Filtration through a 0.22 µm PVDF sterilizing-grade filter is run at applied pressure ≤1.5 bar; pre-filtration bioburden is controlled to ≤10 CFU/100 mL under 21 CFR 211.113. The filtered solution is held in a jacketed stainless steel vessel at 2–8 °C for no more than 24 h before filling. Terminal sterilization is performed at 121 °C for 15 min, producing F₀ ≥ 8. Where heat-sensitive degradation product would exceed 0.5% at that cycle, a 115 °C for 30 min cycle is evaluated under worst-case bioburden assumptions. Release testing includes Ph. Eur. 2.6.1 sterility, Ph. Eur. 2.6.14 bacterial endotoxins, USP <790> visible particulates, and Ph. Eur. 2.9.5 uniformity of mass. Multi-dose vials with preservative systems are challenged under Ph. Eur. 5.1.3. Terminal product types include single-dose vials of 20 mL, 50 mL, and 100 mL and preserved multi-dose vials. Operating boundary: the bulk solution pH remains below 8.0 when the API contains ester functionalities because higher alkalinity can push hydrolytic degradation beyond the shelf-life specification.

If Dry Ruminant Premix Loading Falls Below 3.0% w/w, Ordered Mixing and Granulation Replace Bulk Blending

Dry ruminant premix production with API loadings of 0.5–3.0% w/w cannot rely on simple bulk blending because free-flowing powders segregate under vibration and hopper discharge. The tincture-grade veterinary API is therefore fixed onto a crystalline carrier before dilution. Ordered mixing is conducted in a ribbon blender with a lactose monohydrate carrier having D₅₀ 200–500 µm; the API is milled to D₅₀ 45–90 µm before charging. A granulation binder, povidone K30 dissolved in purified water at 5–10% w/w, is sprayed at 1.5–2.0 kg/min into a high-shear granulator operating at impeller speed 150–300 rpm and chopper speed 1500–3000 rpm. The medicated premix addition ratio is 1.0–5.0% w/w, with overage capped at 5% of label claim to offset processing loss. Wet mass is passed through a 1.5 mm screen and dried in a fluidized-bed dryer with inlet air temperature 50–65 °C, product temperature 32–40 °C, and final loss on drying ≤2.0%. Milled granules are sieved to 150–850 µm; content uniformity is tested according to USP <905> and Ph. Eur. 2.9.5, with acceptance RSD ≤5.0%. Sequential feed dilution into finished cattle or sheep feed reaches final API concentrations of 0.1–0.5% w/w; carryover after batch changeover is verified by HPLC not to exceed 1.0% of the next batch labeled amount. Terminal product types include 5 kg, 10 kg, and 25 kg premix bags and pelleted feed supplements. Operating boundary: at relative humidity above 60%, both carrier and API require pre-drying before ordered mixing because moisture-induced aggregation shifts content uniformity across the hopper discharge profile.

Poultry drinking-water powder and granule production is constrained less by segregation than by dissolution time and nozzle clogging in proportioner systems. The tincture-grade veterinary API is wet-granulated with lactose monohydrate or dextrose at an API addition ratio of 10–30% w/w of the finished powder, with an effervescent carrier pair of citric acid 10–15% w/w and sodium bicarbonate 10–15% w/w to generate dispersion turbulence in cold water. Granulation uses purified water or 30–50% v/v ethanol as the binder solvent in a fluidized-bed granulator at inlet air temperature 45–60 °C; final moisture is dried to ≤1.5% via loss on drying under Ph. Eur. 2.2.32. Granules are milled to 100–200 µm to avoid segregation while retaining wettability. Dispersion performance is tested by adding a 5 g sample to 1 L of hard water at 10 °C; complete dispersion within 3 min is the release target. The stock solution is prepared at 0.01–0.05% w/v active concentration, and the proportioner line requires an inline 100 µm screen before the dosing pump. Release testing uses Ph. Eur. 2.9.1 for dispersion, Ph. Eur. 2.6.13 for non-sterile microbial limits, Ph. Eur. 2.9.5 for uniformity, and 21 CFR 211.165 for finished product release. Terminal product types include 100 g, 500 g, and 1 kg laminated foil sachets and high-density polyethylene jars. Operating boundary: if the API has poor acid stability, the citric acid component is reduced or removed to prevent pH-dependent degradation in stock solutions held longer than 24 h at farm level.

Aquaculture Floating Feed Extrusion and Leaching Constraints

Aquaculture premix applications subject the veterinary API to a downstream extrusion environment in which heat and moisture can reduce final potency before the medicated pellet reaches the animal. The API is diluted in a second-stage ribbon blender with calcium carbonate or wheat middlings as carrier to a premix concentration of 1.0–5.0% w/w; final feed concentration is typically 0.2–2.0% w/w according to species and therapeutic dose. Extrusion is conducted in a twin-screw extruder with barrel temperature profile 90–110 °C and die diameter 1.5–3.0 mm. Because published data for this specific configuration is limited, retention time and specific mechanical energy are verified by process challenge runs with a marker tracer to confirm API recovery above 90%. Pellet binding and water stability are assessed by soaking 10 g of extruded feed in 1 L of water at 25 °C for 30 min; leached API is quantified by HPLC and should not exceed 15% of labeled content. Feed hygiene compliance is maintained under Regulation (EC) No 183/2005, and the premix batch record must document homogeneous distribution with RSD ≤5% under USP <905> sampling. Terminal product types include 20 kg and 25 kg woven polypropylene bags with inner polyethylene liner, and sinking or floating pellets of 2 mm, 2.5 mm, or 3 mm. Operating boundary: if API decomposition onset approaches 130 °C, the extrusion barrel must not exceed 120 °C in the final two zones.

Viscosity Measurements Alone Underpredict Equine Oral Syringe Failure at 4°C

Low-temperature storage of equine oral paste can raise plastic viscosity above the syringeability threshold even when the 25 °C viscosity specification appears acceptable. The tincture-grade veterinary API is dispersed at 5.0–20.0% w/w into a vehicle containing medium-chain triglycerides, microcrystalline cellulose, and xanthan gum; the aqueous wetting phase is blended in a vacuum planetary mixer at −0.06 MPa to remove entrapped air. Viscosity is measured by Brookfield RV spindle 7 at 10 rpm and 25 °C; the target range is 50,000–150,000 mPa·s according to Ph. Eur. 2.2.10, while the 4 °C sample must remain below 250,000 mPa·s to ensure syringeability. Batch homogeneity is verified by assay of top, middle, and bottom zones after 60 min mixing; RSD ≤5.0% under USP <905> is required. Filling is performed into HDPE single-dose syringes at 10–30 mL fill volume; fill weight variation is controlled under Ph. Eur. 2.9.5. For oral solution variants, the API is dissolved or suspended at 1.0–10.0% w/v in a co-solvent system of purified water and 10–20% v/v propylene glycol; the final solution is filtered through a 20 µm inline strainer and filled into amber glass bottles with tamper-evident caps. Terminal product types include single-dose oral syringes, multi-dose press-in plunger tubes, and 100 mL or 250 mL oral solutions. Operating boundary: glycerol above 20% w/w in the vehicle is avoided because syneresis and phase separation can occur at low temperature, and the API should not be milled below 10 µm if it is prone to agglomeration in lipophilic media.